权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing a kinase inhibitor drug to treat spinal cord injury

开发治疗脊髓损伤的激酶抑制剂药物

基本信息

批准号：
10338372
负责人：
Hassan Al-Ali
金额：
$ 65.03万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-04 至 2023-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10338372
关键词：
Address Adult Animal Model Animal Testing Axon Biological Assay Bladder Brain Breathing Cells Centers for Disease Control and Prevention (U.S.)Chemicals Chemistry Chronic Clinical Clinical Trials Complex Development Drug Kinetics Drug Targeting Economic Burden Effectiveness Failure Family Generations Goals Growth Health Insurance Healthcare Healthcare Systems Heart In Vitro Individual Injury Intellectual Property International Intestines Investigation Lead Legal patent Life Machine Learning Metabolism Modeling Motivation Mus Natural regeneration Neuraxis Neurons Paralysed Patients Persons Pharmaceutical Preparations Phase Phase I Clinical Trials Phenotype Phosphotransferases Property Protocols documentation Rattus Regenerative capacity Reproducibility Research Risk Series Sexual Dysfunction Source Spinal Cord Spinal cord injury Structure-Activity Relationship Synthesis Chemistry Testing Therapeutic Thinking Toxic effect Toxicology United States National Institutes of Health Work absorption analog axon growth axon injury axon regeneration base central nervous system injury clinical candidate cost drug candidate drug development improved in vivo in vivo evaluation inhibitor therapy injured kinase inhibitor lead candidate lead optimization neuron loss novel novel therapeutic intervention painful neuropathy preclinical development psychologic screening small molecule therapeutic candidate translational potential

项目摘要

ABSTRACT Spinal cord injury (SCI) is a devastating condition with life-long consequences that include paralysis. Central nervous system (CNS) axons typically fail to regenerate, leading to irreversible losses of neuronal connectivity and associated functions after injury. SCI is now estimated to cost the nation’s healthcare system around $40.5 billion annually (CDC). People living with paralysis are often unable to afford health insurance that adequately covers the associated complex secondary or chronic conditions, which places tremendous economic burden and psychological suffering on them and their families. Developing a drug to treat SCI will address major healthcare and societal needs. Encouraging axon regeneration in the CNS is challenged by at least two separate mechanisms that suppress axonal growth: 1) a lack of intrinsic regenerative capacity in adult CNS neurons, and 2) the extrinsic inhibitory microenvironment confronting damaged axons. Despite decades of research and billions of NIH dollars spent, there are still no approved drugs for promoting axon regeneration. Moreover, the effectiveness of drugs in development is likely limited by the fact that each targets only one of the two growth-suppressive mechanisms. We have discovered the first therapeutic candidate, in the form of a small molecule, which can simultaneously address both sources of regeneration failure. We accomplished this using a combination of phenotypic screening, target-based profiling, and machine learning to identify kinase targets within each of the two mechanisms, extrinsic and intrinsic. We then identified a single small molecule (RO48) that manifests a polypharmacology profile correlated with unusually robust promotion of axon growth. Remarkably, RO48 showed high and reproducible efficacy in multiple animal models of SCI. We performed preliminary structure activity relationship (SAR) studies on RO48 with three main motivations: 1) preliminary investigation of the SAR and hit- to-lead feasibility, 2) improving the potency of RO48 in cell-based assays, and 3) generation of new composition of matter IP to permit drug development. We were successful in demonstrating SAR and feasibility, as well as generating new IP (International Patent Application No. PCT/US18/58411, inventors: Al-Ali et al.). Preliminary in vitro and in vivo DMPK/Tox studies revealed that our chemistry efforts thus far have already eliminated several liabilities of RO48. In this project, we aim to finalize the SAR studies and generate four lead candidates for animal testing. We will then prioritize one lead to advance towards a Phase I clinical trial.

摘要